Results 181 to 190 of about 27,407 (265)

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.

JAMA Netw Open
Chung MC, Yu TM, Wu LY, Wu MJ, Shieh JJ, Chung CJ.   +5 more
europepmc   +1 more source

Diabetic remission in a newly diagnosed diabetic cat treated with SGLT2 inhibitor. [PDF]

JFMS Open Rep
Lodarski F, Benchekroun G, Cervone M.
europepmc   +1 more source

A Prospective Study on the Metabolic and Hormonal Outcomes of SGLT2 Inhibitor Combination Therapy With and Without Metformin in Newly Diagnosed Type 2 Diabetes Mellitus. [PDF]

Biomedicines
Aftab R, Fawwad A, Abbas E, Nangrejo R, Fatima F, Shahid SM.   +5 more
europepmc   +1 more source

SGLT2 independent effects of the SGLT2 inhibitor empagliflozin

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off ...
openaire   +2 more sources

Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González, Alejandro Matamoros‐Domínguez, Juan Manuel Espinosa‐Cabello, Gisela Pérez‐Muñoz, Manuel Jesús León Aranda, María Del Carmen Roque‐Cuellar, Silvia García‐Rey, Andrés Jiménez‐Sánchez, Antonio Jesús Martínez‐Ortega, Miguel Ángel Mangas‐Cruz, Isabel Cerrillo, Javier S. Perona, Pedro Pablo García‐Luna, Elena María Yubero‐Serrano, José María Castellano   +14 more
wiley   +1 more source

SGLT2 inhibitor therapy in diabetic cats: first clinical experiences with non-ideal candidates. [PDF]

J Feline Med Surg
Vanneste A, Van Heuckelom E, Vannieuwenhuyse D, De Voogt C, Daminet S.   +4 more
europepmc   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings. [PDF]

Kidney Med
Hangaard Olesen R, Carlson N, Søndergaard J, Freese Ballegaard EL, Borg R, Ehlers LH.   +5 more
europepmc   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study. [PDF]

Infect Dis Ther
Ngiam JN, Loy EX, Koh MCY, Chiew CJ, Li RJ, Lim SC, Tai ES, Bee YM, Chow WL, Lye DCB, Chia YW, Chan MYY, Hausenloy DJ, Tan KB, Wee LE.   +14 more
europepmc   +1 more source